Clinical Trial Detail

NCT ID NCT03162627
Title Selumetinib and Olaparib in Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

Advanced Solid Tumor

ovarian cancer

endometrial cancer

Therapies

Olaparib + Selumetinib

Age Groups: adult senior

Additional content available in CKB BOOST